Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 8, 2007, Pages 919-927

  Garey, Kevin W ^a   Pai, Manjunath P ^b   Suda, Katie J ^c   Turpin, Robin S ^d,e   Rege, Milind D ^a   Mingo, Dana E ^f   Bearden, David T ^g  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f Memphis Pathology Laboratory   (United States)

^g OREGON STATE UNIVERSITY   (United States)

Author keywords

Candidemia; Cohort study; Fluconazole; Guidelines

Indexed keywords

AMPHOTERICIN; CASPOFUNGIN; CORTICOSTEROID; CREATININE; FLUCONAZOLE;

ADULT; AGED; ARTICLE; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG USE; FEMALE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HEMODIALYSIS; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MEDICATION ERROR; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; UNITED STATES; WEIGHT GAIN;

ADULT; AGED; ANTIFUNGAL AGENTS; BODY WEIGHT; CANDIDA; CANDIDA GLABRATA; CANDIDIASIS; COHORT STUDIES; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 34548247141     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1365     Document Type: Article

References (32)

1. Miller LG, Hajjeh RA, Edwards JE, Jr. Estimating the cost of nosocomial candidemia in the United States. Clin Infect Dis 2001; 32(7): 1110.
2. Morgan J. Global trends in candidemia: review of reports from 1995-2005. Curr Infect Dis Rep 2005; 7(6): 429-439.
3. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37(9): 1172-1177.
4. Wilson AG, Micek ST, Ritchie DJ. A retrospective Evaluation of fluconazole for the treatment of Candida glabrata fungemia. Clin Ther 2005; 27(8): 1228-1237.
5. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27(4): 781-788.
6. Ben-Abraham R, Keller N, Teodorovitch N, et al. Predictors of adverse outcome from candidal infection in a tertiary care hospital. J Infect 2004; 49(4): 317-323.
7. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49(9): 3640-3645.
8. Bouza E, Sousa D, Munoz P, Rodriguez-Creixems M, Fron C, Lechuz JG. Bloodstream infections: a trial of the impact of different methods of reporting positive blood culture results. Clin Infect Dis 2004; 39(8): 1161-1169.
9. Clancy CJ, Yu VL, Morris AJ, Snydman DR, Nguyen MH. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005; 49(8): 3171-3177.
10. Lee SC, Fung CP, Huang JS, et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000; 44(10): 2715-2718.
11. Antoniadou A, Torres HA, Lewis RE, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003; 82(5): 309-321.
12. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis 2004; 23(5): 380-388.
13. Marr KA, White TC, van Burik JA, Bowden RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997; 25(4): 908-910.
14. Xu J, Ramos AR, Vilgalys R, Mitchell TG. Clonal and spontaneous ozigins of fluconazole resistance in Candida albicans. J Clin Microbiol 2000; 38(3): 1214-1220.
15. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. NCCLS: Wayne, PA, 2002.
16. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38(2): 161-189.
17. Buchner T, Fegeler W, Bernhardt H, et al. Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators. Eur J Clin Microbiol Infect Dis 2002; 21(5): 337-352.
18. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev 2005(4): CD003539.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31-41.
20. Cousin L, Berre ML, Launay-Vacher V, Izzedine H, Deray G. Dosing guidelines for fluconazole in patients with renal failure. Nephrol Dial Transplant 2003; 18(11): 2227-2231.
21. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65(14): 2049-2068.
22. Cha R, Sobel JD. Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infect Ther 2004; 2(3): 357-366.
23. Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41(10): 1455-1460.
24. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of blood-stream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42(4): 1519-1527.
25. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100(6): 617-623.
26. Voss A, de Pauw BE. High-dose fluconazole therapy in patients with severe fungal infections. Eur J Clin Microbiol Infect Dis 1999; 18(3): 165-174.
27. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47(10): 3165-3169.
28. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42(5): 1105-1109.
29. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A. Treatment of Candida albicans fungaemia with fluconazole. J Infect 1993; 26(2): 133-146.
30. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288(14): 1723-1727.
31. Herbrecht R, Natarajan-Ame S, Nivoix Y, Letscher-Bru V. The lipid formulations of amphotericin B. Expert Opin Pharmacother 2003; 4(8): 1277-1287.
32. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43(1): 25-31.